Lipid droplet formation and subsequent steatosis has been reported to contribute to hepatotoxicity and is an adverse effect of many pharmacological agents including the anti-epileptic valproic acid (VPA). In this study, we have developed a simple model system Dictyostelium discoideum to investigate the effects of VPA and related compounds in lipid droplet formation. In mammalian hepatocytes, VPA increases lipid droplet accumulation over a 24 hour period giving rise to liver cell damage, and we show a similar effect in Dictyostelium following 30 minute VPA treatment. Using 3 H-labelled poly-unsaturated (arachidonic) or saturated (palmitic) fatty acids, we shown VPA treatment of Dictyostelium gives rise to an increased accumulation of both fatty acids in phosphatidylcholine, phosphatidylethanolamine and non-polar lipids in this time period, with a similar trend observed in Human hepatocytes (Huh7 cells) labelled with 3 H-arachidonic acid. In addition, pharmacological inhibition of β-oxidation in Dictyostelium phenocopies fatty acid accumulation, in agreement with data reported in mammalian systems. Using Dictyostelium, we then screened a range of VPA-related compounds to identify compounds with high and low lipid-accumulation potential, and validated these activities for effects on lipid droplet formation using human hepatocytes. Structure-activity relationships for these VPA-related compounds suggest that lipid accumulation is independent of VPA-catalysed teratogenicity and inositol depletion. These results suggest that Dictyostelium may provide both a novel model system for the analysis of lipid droplet formation in human hepatocytes and a rapid method for identifying VPA-related compounds showing liver toxicology.
Introduction
Valproic acid (VPA) was first identified as an antiepileptic in 1963 (Meunier et al. 1963 ) and since then it has become a commonly used treatment for epilepsy, bipolar disorder and migraine (Lagace et al. 2005; Terbach and Williams 2009) . In trying to understand the therapeutic role of VPA, a range of cellular effects have been identified including inositol depletion (associated with bipolar disorder treatment (Eickholt et al. 2005; Shimshoni et al. 2007; Williams 2005; Williams et al. 2002) ) and histone deacetylase (HDAC) inhibition (associated with teratogenicity (Gottlicher et al. 2001; Phiel et al. 2001) ).
In addition, VPA is associated with a range of adverse effects including hepatotoxicity, tremors, alopecia and drowsiness (Lagace et al. 2005) . Hepatotoxicity is more severe in those patients on multiple prescriptions; however the related condition of non-alcoholic fatty liver disease or steatosis (abnormal lipid accumulation) is also frequent in patients taking VPA, alone or in combination with other agents (Luef et al. 2009; Verrotti et al. 2011a) . Thus the analysis of hepatotoxicity and steatosis in relation to VPA treatment, and the development of model systems for this research are important priorities as they will enable the development of novel therapeutics with improved risk:benefit ratios.
Within mammalian cells, fatty acids such as the polyunsaturated fatty acid arachidonic acid (AA) (Svennerholm 1968 ) may be incorporated into phospholipids directly or stored as non-polar lipids such as diacyl and triacylglycerols (DAG/TAGs) prior to reincorporation or metabolism. Release of the fatty acid from these phospholipids or other lipid classes occurs mainly through lipase-catalysed catabolism such as phospholipase A2 (PLA 2 ) (Rapoport 2008) . Once released, free (non-esterified) fatty acid species may then be re-incorporated or transported to the mitochondria to be metabolised by β-oxidation. VPA treatment has been shown to act as a PLA 2 -like inhibitor (Bosetti et al. 2003; Rapoport and Bosetti 2002) , reducing expression of defined isoforms of PLA 2 (Chang et al. 2001) while also disrupting fatty acid βoxidation (Aires et al. 2011; Silva et al. 2008) . A range of in vitro mammalian models have been used to show VPA-induced hepatotoxicity and steatosis effects (Eadie et al. 1988 ) with increased lipid droplet accumulation observed in hepatocytes (Fujimura et al. 2009 ) and skeletal muscle (Melegh and Trombitas 1997) . Whilst this VPA-catalysed effect is likely to cause liver damage to individuals undergoing treatment, it remains possible that these effects may be disassociated from the therapeutic mechanisms; thus a better understanding of compounds causing this effect is of interest in the design of novel therapeutics.
Structure activity relationship (SAR) studies have previously been employed to delineate the potential targets of VPA (Bialer et al. 2010; Eickholt et al. 2005; Eikel et al. 2006; Eyal et al. 2005; Shimshoni et al. 2007) . In this approach, the structural characteristics of VPA-related compounds can be used to isolate and characterise the molecular mechanism of individual effects which can then be used to differentiate between distinct mechanisms of action. SAR studies have been used to examine the teratogenic nature of VPA which is thought to be due to inhibition of histone deacetylase function (Eikel et al. 2006; Phiel et al. 2001; Spiegelstein et al. 2000) . Similarly, the inhibition of inositol phosphate signalling by VPA has also been examined in SAR studies in both Dictyostelium cells and mammalian neurons (Eickholt et al. 2005; Shimshoni et al. 2007; Williams et al. 2002) . These previous studies have clearly identified distinct structural characteristics of VPA-related compounds responsible for these effects and therefore are likely to have different mechanisms of action. It remains unclear if either of these effects is related to lipid accumulation, which is the aim of the current investigation.
In this study, we have examined VPA-induced lipid accumulation in Dictyostelium discoideum. We have previously used this model to characterise the effect of VPA in inositol trisphosphate (InsP 3 ) (Eickholt et al. 2005; Shimshoni et al. 2007; Williams et al. 2002) and phospholipid (Chang et al. 2009; Xu et al. 2007) signalling, with subsequent translation in mammalian systems. Here we show that in Dictyostelium, pharmacologically-relevant concentrations of VPA acutely enhance the uptake of fluorescently-labelled and radio-labelled fatty acids (both poly-unsaturated fatty acid [ 3 H]-AA and the saturated fatty acid [ 3 H]-PaA (palmitic acid)), and that the increase in fatty acid uptake occurs concurrently with a decrease in fatty acid release. Analysis of the cellular distribution of incorporated, radio-labelled fatty acids by 2dimensional TLC revealed that VPA-induced fatty acid accumulation increased the overall accumulation in all phospho-and non-polar lipids examined but did not alter the overall distribution within lipids, and an equivalent trend is shown using human hepatocytes (Huh7 cells) following [ 3 H]-AA labelling. In Dictyostelium, a similar effect of lipid accumulation is shown by pharmacological inhibition of oxidation. Analysis of series of VPA-related compounds in Dictyostelium identified a broad range of activities, tightly defined by structure, and a selection of these compounds was then used in human hepatocytes (Huh7 cells) to show corresponding lipid accumulation. Finally, using a range of compounds with known teratogenic or inositol-depleting activity, we show the biological effect of VPA-induced fatty acid accumulation may be independent of inositol depletion and HDAC inhibition/teratogenicity indicating the potential for identifying VPA-based therapeutics with reduced hepatotoxic liability.
Materials & Methods

Reagents
3 H arachidonic acid was purchased from Hartmann analytic (Germany); 3 H palmitic acid was from Perkin Elmer (Cambridge, UK). VPA related compounds were provided by Heinz Nau, Sigma Aldrich UK, Alfa Aesar Ltd, ChemSampCo Ltd., TCI Europe, Avocado, ACC Corporation, Katwijk Chemie and VWR.
Dictyostelium media was supplied by Formedium (Norfolk, UK). Isoproyl-pentanoic acid (PIA), (2R)isopropyl-pentamamide (PID), 2,2,3,3-tertramethylcyclopropanecarboxylic acid (TMCA), 3-methyl-2isopropylbutanoic acid and 4-methylpentanoic acid were generously provided by Prof M. Bialer (The Hebrew University of Jerusalem, Israel). All reagents were supplied by Sigma Aldrich (Poole, UK).
Cells and development
Dictyostelium cells were grown in axenic medium or on Sussman's agar plates in association with Raoultella planticola (Drancourt et al. 2001) . Dictyostelium cells were artificially developed by placing in phosphate buffer (16.5mM KH2PO4, 3.8mM K2HPO4) and pulsing with 25nM cAMP every 6 minutes for 4 hours at 20 o C. Cell labeling was carried out by the addition of radio-labelled lipid to pulsing cells for a further 60 minutes (Boeckeler et al. 2006 ). The Huh7 human hepatocellular carcinoma cell line (Nakabayashi et al. 1982 ) was a kind gift from Dr Steve Hood (GSK, Ware, UK). All cells were routinely cultured in 75 cm 2 vented tissue culture flasks (Nunc, UK) using minimal essential medium with Earle's salts supplemented with 1% non-essential amino acids, 2 mM L-glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin and 10% foetal bovine serum. In order to maintain phenotypic consistency, Huh7 cells were only used for three weeks (approximately 5 passages) following recovery from liquid nitrogen. For imaging analysis, 1 x 10 5 cells were seeded into 6 well plates containing sterile coverslips or 2.5 x 10 4 cells seeded into 24 well plates.
Cells were allowed to adhere at 37°C for >2 hours prior to treatment as indicated in figure legends.
Lipid droplet analysis
Oil Red-O staining was performed on cells fixed overnight in 10% formalin (3.7% formaldehyde) in PBS before washing twice with 70% ethanol and water. Cells were stained with 0.18% oil Red-O for 10 minutes, washed with ethanol and water prior to hematoylin counterstain.
Fatty acid uptake and release
For fatty acid uptake, Dictyostelium cells were pulsed with cAMP (as above) for 4 hours in shaking liquid culture at 2.5 x 10 6 cells/ml prior to the addition of 0.25µCi of 3 H-labelled fatty acid added in 0.5% fatty acid free BSA at which point drugs were also added at the indicated concentrations. Samples were taken at indicated times (by removing about 7.5 x 10 5 cells for scintillation counting and 3 x 10 7 cells for TLC analysis and washing once in phosphate buffer).
For fatty acid release experiments, cells were pulsed (as above) for 4 hours at 1.5 x 10 6 cells/ml. Cells were then labelled by resuspending in phosphate buffer with 0.5% fatty acid free BSA and 0.25µCi of 3 Hlabelled fatty acid for 1 hour. Unincorporated 3 H was removed by washing twice in phosphate buffer.
Cells were finally resuspended in phosphate buffer/BSA at 5 x 10 6 cells/ml and 300µl samples (5%) removed at indicated time points. Samples were briefly centrifuged to remove cells and 250µl of supernatant was removed for scintillation counting. 1D TLC analysis was performed as previously described (Pawolleck and Williams 2009 ). Briefly, lipids were extracted from cells with 2:1 chloroform: methanol, dried and separated using the TLC solvent 40:15:13:12:7 chloroform:acetone:methanol:acetic acid:distilled water. 2D TLC analysis was performed on lipids extracted as previously described (Garbus et al. 1963) . Lipids were separated first in a basic solvent (chloroform: methanol: ammonium hydroxide, 65:25:4, v/v/v) followed, in the second dimension, by an acidic solvent (n-butanol: acetic acid: water, 90:20: 20, v/v/v). Plates were sprayed with 0.2% (wt/vol) 8-anilino-4-naphthosulphonic acid (ANSA) in methanol prior to visualisation under UV fluorescence. Quantification of spots was performed by phosphorimaging or scraping of spots and scintillation counting.
Statistical analysis
Graphical and statistical analysis was carried out using Graphpad Prism software. Error bars show +/standard error of mean (SEM) and statistical significance was carried out using Student's t test. All data represent at least n ≥ 3. Fatty acid uptake and release data are expressed as a % cpm of control.
Results
VPA increases fatty acid accumulation
To investigate the utility of using Dictyostelium to analyse lipid droplet formation following VPAtreatment, we visualised VPA-induced fatty acid accumulation with a compound containing a 12 carbon fatty acid chain linked to a fluorescent head group (C 1 -BODIPY-C 12 ) (von Lohneysen et al. 2003; Worsfold et al. 2004) . Upon incubation of cells with C 1 -BODIPY-C 12 -labelled lipid, VPA (0.5 mM) caused a large increase in the intensity and a small but significant increase in diameter of fluorescent lipid droplets within cells compared to untreated cells ( Fig. 1a, b) . These changes were observed after only 30 minute treatment with VPA and are comparable to the lipid accumulation observed in hepatocytes after 24 hours (Fujimura et al. 2009 ).
To quantify this effect of increase lipid accumulation in Dictyostelium, we measured the uptake of 3 H-AA fatty acid into cells over time, to show linear incorporation over a 30 min period ( Fig. 2a ). VPA caused a dose-dependent increase in 3 H-AA fatty acid incorporation, with an EC50 of 47 µM ( Fig. 2a insert) . This effect is not fatty acid specific since similar results were also seen using 3 H-PaA, with an EC50 value of 160 µM VPA ( Fig. 2b and insert). For both fatty acids, increased uptake was significant following 30 min treatment (p<0.05). These results were confirmed following lipid extraction and 1D TLC separation with duplicate samples following 30 and 60 min VPA (0.5mM) treatment ( Fig. 2 c-d ).
We also assessed the release of radio-label into medium from cells labelled with either 3 H-AA or 3 H-PaA.
In both cases, the release of radio-label was linear over a 30 min period ( Fig. 2e-f ). Inhibition of this release by VPA (0.5 mM) was acute and dose-dependent, with an IC50 of 89 µM and 163 µM for 3 H-AA and 3 H-PaA respectively ( Fig. 2e -f inserts), with both 3 H-AA and 3 H-PaA labelled cells showing a significant reduction in 3 H release after 30 min exposure (0.5mM) (p<0.05). This provided a fast and easy assay for determining the deregulation of fatty acid accumulation by VPA in Dictyostelium.
We then examined the specific phospholipid classes involved in increased fatty acid incorporation regulated by VPA. In these experiments, Dictyostelium cells were labelled for 60 min with 3 H-AA or 3 H-PaA in the absence or presence of VPA (1 mM), and then lipids were extracted and separated by 2D TLC prior to quantification by scintillation counting. Equal lipid loading was validated by UV visualisation of 2D separated lipids ( Fig. 3a and b) . VPA treatment caused a strong and significant increase in incorporation of both 3 H-AA and 3 H-PaA into phosphatidylcholine (PC) and phosphatidylethanolamine (PE) ( Fig. 3c, d ). VPA did not alter the preference of phospholipid species retaining each fatty acid, suggesting the mechanism of action is not restricted to a specific class of lipid. As well as phospholipid incorporation, TLC analysis revealed a significant increase in fatty acid accumulation in non-polar lipids ( Fig. 3c, d) which correlates with the observed lipid droplet accumulation in Dictyostelium and hepatocytes. Repeating the 3 H-AA labelling experiments in a human hepatocytes cell line (Huh7), showed a similar trend to increased incorporation into phospholipids and non-polar lipids (Fig. 3e ).
Inhibition of -oxidation partially phenocopies VPA regulation of fatty turnover
To investigate the mechanism of VPA-induced lipid accumulation, we assessed the role of inhibiting various lipid-turnover associated enzymes on 3 H-AA in Dictyostelium using a pharmacological approach ( Fig. 4a ). Since VPA has been associated with a PLA 2 -inhibitory like effects (Bosetti et al. 2003; Rapoport and Bosetti 2002) , we first used a combination of PLA 2 class-specific inhibitors (BEL [80 μM], a Ca 2+independent PLA 2 inhibitor (Ackermann et al. 1995) ; MAFP [50 μM], an inhibitor of Ca 2+ -dependent and Ca 2+ -independent cytosolic PLA 2 Lio et al. 1996) ; and BPB [20 μM], a general phospholipase A 2 inhibitor (Mitchell et al. 1977) ). This PLA 2 -inhibitor cocktail gave the opposite effect to VPA showing reduced fatty acid accumulation (Fig. 4b) . Similarly, the reduction of diacylglycerol (DAG) acyltransferase activity, responsible for conversion of diacylglycerol to triacylglycerol using an acyl-CoA substrate (with the inhibitor xanthohumol,50 M), also inhibited fatty acid accumulation. However, the use of 2-mercaptoacetate (2-MA; 15 mM) previously shown to inhibit long-chain acyl-CoA dehydrogenase in the -oxidation of fatty acids (Bauche et al. 1983) , phenocopied the effect of VPA by causing an increase in fatty acid uptake ( Fig. 4b ). Combining VPA and 2-MA ( Fig. 4c ) gave rise to a significant increase in uptake (p= 0.04) above VPA-alone, and similar to that of 2-MA alone, suggesting that VPA may function in this effect by weakly inhibiting the -oxidation of fatty acids.
Structure-Activity study of fatty acid accumulation in Dictyostelium
To examine the structural features of VPA that affect fatty acid regulation we employed a range of compounds related to VPA with varying carbon backbone and side chain length, head group and saturation. Radio-label release from 3 H-fatty acid-labelled cells following 60 min (0.5 mM) treatment was measured (Fig. 5 ). The compounds tested showed a range of inhibitory activity, from stronger than VPA to no change from control. Compounds showing high inhibitory activity were carboxylic acids, branched at the second carbon, with the strongest compound containing an isopropyl group. Branched compounds were generally stronger than corresponding straight chains, with a preference for longer side chains (propyl groups showing stronger inhibition than methyl side chains).
Correlating Dictyostelium fatty acid effects and steatosis
Since our data suggests a spectrum of fatty acid-regulating activities for the VPA-related compounds tested, we then examined the effects of a set of these compounds (showing a wide range of activities) on lipid droplet accumulation in human hepatocytes (Huh7 cells). In these experiments, Huh7 cells were exposed to VPA or these related compounds for 24 hours prior to staining of lipid droplets and image recording (Fig. 6 ). Compounds showing little attenuation of fatty acid release in Dictyostelium did not produce lipid droplets in hepatocytes (Fig. 6 a, c, e and f), and compounds showing VPA-like inhibitory effect on fatty acid release in Dictyostelium had a VPA-like effect on lipid droplet formation in the human cells ( Fig. 6 b, d, and g) . Finally compounds showing a stronger attenuation of fatty acid release Dictyostelium compared to VPA also showed enhanced lipid droplet formation in hepatocytes ( Fig. 6h and i).
Distinguishing fatty acid, inositol depletion and teratogenic effects
VPA and related compounds have been widely shown to cause the potentially therapeutic effect of inositol depletion, and the side effect of teratogenicity (Terbach and Williams 2009 ). We thus compared activities for compounds of known efficacy in inositol depletion, as previously shown in both Dictyostelium InsP 3 depletion and mammalian dorsal root ganglia (DRG) neuronal explant experiments, and in teratogenicity (Table 1) with effects shown here on fatty acid regulation (in Dictyostelium) and lipid droplet formation in huh7 cells. No relationship was found between inositol depletion efficacy and regulation of fatty acids. For example, 2-methyl-2-pentenoic acid was shown to reduce inositol trisphosphate (InsP 3 ) in Dictyostelium and to elicit an inositol-dependent increase in growth cone size in primary rat dorsal root ganglia (Eickholt et al. 2005 )and we show here that it did not affect fatty acid regulation in Dictyostelium. In contrast, 2-ethyl-4-methylpentanoic acid had a strong (VPA-like) effect on release from fatty acid-labelled cells and was strongly effective in inositol depletion in both Dictyostelium and DRG experiments. Similarly, in regards to teratogenicity (Table 1) , no correlation was shown for compounds when comparing lipid regulation and teratogenic activities (Eickholt et al. 2005; Riebeling et al. 2011) .
Discussion
Lipid droplet formation in the liver, steatosis, has been associated with hepatotoxicity (Stephens and Levy 1992) , and is commonly associated with VPA treatment, although the mechanism giving rise to this effect remains unclear (Lagace et al. 2005) . Understanding the molecular mechanism for this effect has been difficult since VPA gives rise to numerous molecular effects, many of which have not yet been full elucidated nor have the effects and pathways been correlated (Terbach and Williams 2009 ). To unravel the multiple biochemical effects of VPA, we have developed a simple biomedical model, Dictyostelium Boeckeler et al. 2006; chang et al. 2011; Eickholt et al. 2005; Ludtmann et al. 2011; Terbach et al. 2011; Williams et al. 2002; Xu et al. 2007 ). Subsequent to indentifying molecular effects of VPA in Dictyostelium, we have then applied this knowledge to mammalian systems to validate the model. Here we investigate the effect of VPA in lipid accumulation and correlate effects shown in Dictyostelium to human liver cells. In this process we have identified a rapid method for examining lipid accumulation using Dictyostelium and successfully translated results from this model to a mammalian cell line to identify VPA-related compounds exhibiting reduced lipid accumulation. We also show this effect is likely to be unrelated to other VPA-mediated effects of teratogenicity and inositol depletion.
The identification of analogues with reduced hepatotoxic potential is, therefore, of particular importance in the development of novel therapeutics.
VPA increases the accumulation of lipids in Dictyostelium as observed using both fluorescent labelled and radio-labelled fatty acids ( Figs. 1 and 2) . In the radio-labelled uptake studies, we employed both a polyunsaturated fatty acid, AA, and a saturated fatty acid, PaA; both the fatty acids showed enhanced accumulation and a decreased release of radio-labelled product over time. PaA is a naturally occurring fatty acid in Dictyostelium and although AA is not normally found in the model, it is both incorporated into Dictyostelium phospholipids (Weeks 1976 ) and triggers the complex cellular and biochemical processes involved in Dictyostelium cell movement (Schaloske et al. 2007 ). The conserved nature of this VPA-induced lipid accumulation, observed with both polyunsaturated and saturated fatty acids, suggests a generalised molecular mechanism for VPA in the accumulation of fatty acids within Dictyostelium cells.
The increased accumulation of fatty acids caused by VPA is independent of phospholipid species since the distribution of radio-labelled fatty acids into phospholipid classes did not change with treatment (Fig. 3) . The common trend for an increased fatty acid uptake and incorporation into phospholipids between Dictyostelium and human hepatocytes suggests a relevance of this simple model. VPA also caused an increased accumulation of non-polar lipids in both systems (Fig. 2 and 3) , consistent with an increase in lipid droplet formation since non-polar/neutral lipids typically consist of di-and triacylglycerol species and are stored in these droplets (Kalantari et al. 2010) . These results therefore suggest that Dictyostelium may provide a suitable model for liver fatty acid uptake and steatosis research, and will enable a combined genetic and biochemical approach to be used in the future to better understand this effect.
Although we have shown a linked VPA-induced effect of increased fatty acid uptake and reduced release, the use of a cell biology system for this discovery (rather than purified enzymes in biochemical approaches) makes identifying the cause of these two effects difficult. However, we note that increased lipid droplet formation occurs in presence of only trace quantities of (C 1 -BODIPY-C 12 ) lipid label -a quantity of which is too small to give rise to the substantial increase in lipid droplets upon VPA treatment, thus suggesting a VPA-dependent regulation of existing cellular lipids to increase droplet size (rather than increased uptake) (Fig. 1) . This observation would support a role for VPA and related structures (identified in Fig. 5, 6 and Table 1 ) in regulating cellular fatty acids giving rise to increased incorporation into lipid droplets and reduced release.
To investigate the mechanism of VPA-induced fatty acid accumulation in Dictyostelium, we employed a range of pharmacological inhibitors of fatty acid turnover enzymes to attempt to phenocopy the effect of VPA. Since PLA 2 -catalyses the release of fatty acids and has previously been suggested to regulate PLA 2 -dependent signalling (Chang et al. 2001) , we employed a cocktail of PLA 2 pharmacological inhibitors in our cell-based lipid accumulation assay. The effect of PLA 2 inhibition was to reduce fatty acid accumulation (Fig. 4B) . Similarly, inhibition of DAG acyltransferase also resulted in decreased fatty acid accumulation. These results are consistent with both inhibitors reducing the availability of unesterified positions on the glycerol of phospholipids, thus reducing the incorporation of new fatty acid into these lipids. However, since the effect of -oxidation inhibition was to reproduce fatty acid accumulation in Dictyostelium, our data is consistent with a role for VPA-induced block in -oxidation causing steatosis, although this mechanism is unlikely to be due to inhibition of long-chain acyl-CoA dehydrogenases since effects are additive for each drug.
To define the structural prerequisites for VPA-related compounds in inhibiting fatty acid release in Dictyostelium, we carried out a SARs study. This study identified a range of activities from no inhibition to more active than VPA. Although no clear structural constrains are evident from the compounds tested here, this study provided a rapid means for testing potential lipid regulatory effects of VPA congeners. Using a selection of inactive and highly active compounds identified in the Dictyostelium study, similar efficacies were shown in lipid droplet formation in Human hepatocytes (Huh7 cells). In addition, this study enabled the investigation of a potential overlap between this effect and VPAinduced inositol signalling inhibition and teratogenicity. Here, we compared activity of a range of VPArelated compounds (Fig. 5 ) with varying backbone length, different and side chain length and position, and for inhibitory activity in fatty acid release, teratogenicity (HDAC inhibition) and inositol depletion strengths (Eickholt et al. 2005; Eikel et al. 2006; Shimshoni et al. 2007 ). The structural characteristics of compounds inhibiting fatty acid release are different to those of teratogenicity, since a range of compounds showing enhanced or reduce inositol depletion or teratogenic activity do not shown corresponding activity for this fatty acid-related effect (Table 1) . Fatty acid regulation, teratogenicity and inositol depletion may therefore provide three independent mechanisms of action for VPA in Dictyostelium. This study also provides the first description of VPA-related compounds for the regulation of fatty acid accumulation.
Continued research to understand the molecular mechanisms of lipid droplet formation and subsequent steatosis may help in the development of novel therapeutic treatments with improved risk:benefit ratios. It should be noted that it is not currently clear if the observed lipid droplet accumulation has only detrimental consequences. For example, an increase in free AA has been shown in the brain following seizures Basselin et al. 2003; Bazan et al. 2002; Rintala et al. 1999) , and a reduction in AA signalling has also been observed in both epilepsy and bipolar disorder patient populations following treatment (Basselin et al. 2003; Bazinet et al. 2005) . Our identification of a simple model system to study these effects and the identification of a structural specificity for an effect on fatty acid regulation may provide a potential mechanism for selection of novel therapeutics that lacks the current side effects of weight gain during VPA treatment (Masuccio et al. 2010; Verrotti et al. 2011b; Wirrell 2003) .
In conclusion, we describe the analysis of a VPA-induced change in fatty acid uptake and release in the simple model Dictyostelium. We demonstrate an acute VPA-induced incorporation of fatty acids into complex glycerolipids, consistent with the observed lipid droplet accumulation in hepatocytes. This effect occurs with both a poly-unsaturated and a saturated fatty acid through incorporation into different phospholipids and non-polar lipids in Dictyostelium (and for AA-labelling in hepatocytes) and appears, at least in part, due to a block in -oxidation caused by VPA. We have also identified a range of novel compounds with varying strength of inhibitory effects on fatty acid release, identifying a range of compounds with either enhanced or reduced activity (compared to VPA) and validated this using a human hepatocyte cell line. Finally, this data suggests that the VPA-induced fatty acid regulation is independent of teratogenic or inositol depletion efficacy. *** = p<0.001 vs control, ns = not significant versus control, +++ = p<0.001 vs VPA, ns = not significant versus VPA.
Figure Legends
Figure 6
Lipid droplet accumulation caused by VPA-related compounds in human hepatocytes (imaged) correlates with inhibitory activity for fatty acid release in Dictyostelium (Fig 5) (xx) intermediate reduction; (xxx) high reduction similar to VPA. Rat dorsal root ganglia (DRG) inositol-dependent increase in growth cone area, as shown previously (Eickholt et al. 2005) , was also rated as (YES) or (NO). TMCA = 2,2,3,3-tetramethylcyclopropanecarboxylic acid. -Not determined.
TRANSLATIONAL IMPACT
Clinical issue
Valproic acid (VPA) is commonly prescribed for epilepsy and bipolar disorder, as well as for migraine prophylaxis.
However, despite more than 45 years of research, its mechanisms of action are still unclear. Furthermore, although VPA has several significant side effects, improved therapies based on its structure but without these side
effects have yet to be developed. Among side effects are hepatotoxicity and non-alcoholic fatty liver disease (also known as hepatic steatosis), suggesting that VPA has adverse effects on lipid metabolism in the liver including the formation of lipid droplets in human hepatocytes in vitro. The mechanism of this effect is unclear. The development of model systems to investigate VPA-related compounds with reduced hepatotoxic potential will aid in the development of safer therapies for indications that are treated with this drug.
Results
In this paper, the authors use a simple model system, the social amoeba Dictyostelium discoideum, to analyse the adverse effects of VPA on fatty acid metabolism, and specifically its role in inducing the formation of intracellular lipid droplets. As previously observed in human hepatocytes, they first show that pharmacologically relevant amounts of VPA also cause lipid accumulation in Dictyostelium. Following VPA treatment, fatty acids are taken up and incorporated into specific phospholipids, with a concurrent reduction in fatty acid release, an effect caused at least in part by inhibiting β-oxidation of fatty acids. The authors then use structure-activity analysis to screen a panel of VPA-related compounds for this inhibitory effect, and show that the magnitude of inhibition depends on chemical structural features of the compounds. Testing a selection of these compounds with a range of activities in human hepatocytes indicates a high correlation: compounds that inhibit fatty acid release in Dictyostelium cause lipid droplet formation human hepatocytes, whereas compounds with minimal effect on fatty acid release in Dictyostelium do not induce lipid droplets formation in hepatocytes.
Implications and future directions
This study suggests that Dictyostelium can be used as a non-animal model for analysing the adverse effects of VPA and related compounds on lipid droplet formation. It also identifies novel compounds (and a system to identify more) that have mechanisms similar to VPA but that are unlikely to cause effects on lipid droplet formation in hepatocytes, and should therefore help to identify safer treatments for epilepsy, bipolar disorder and migraine.
